Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study) - Sheng - 2020 - Clinical
Dr. Robier Aguillon Prada, MD – Cleveland, OH | Internal Medicine
Robier Aguillon-Prada's research works | University of Miami Miller School of Medicine, Florida (UM) and other places
Cyclodextrin Protects Podocytes in Diabetic Kidney Disease | Diabetes
Robier A. Aguillon Prada, MD | Critical Care Medicine Doctor in Cleveland, OH
Table 1 from FGF23 induces left ventricular hypertrophy. | Semantic Scholar
Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study) - Sheng - 2020 - Clinical
Robier Aguillon Prada, MD | Cleveland Clinic
Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study) - Sheng - 2020 - Clinical
Supplementary Materials | Science Translational Medicine